Stock PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Market Closed - OTC Markets
Other stock markets
 03:50:43 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.1985 USD +1.07% Intraday chart for Provectus Biopharmaceuticals, Inc. +1.90% +106.77%
Apr. 18 Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose CI
Apr. 16 Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
AQ
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
AQ
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
AQ
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
AQ
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
AQ
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PHARMACEUTICAL-GRADE ROSE BENGAL SODIUM ABSTRACT FOR POSTER PRESENTATION AT 2024 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING
AQ
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
AQ
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
AQ
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
AQ
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
AQ
Provectus: Q3 Earnings Snapshot
AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL PV-10 VACCINE ADJUVANT DATA AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING
AQ
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING
AQ
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SOCIETY FOR MELANOMA RESEARCH 2023 CONGRESS
AQ
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PVCT Stock
  4. News Provectus Biopharmaceuticals, Inc.
  5. Press Releases